AzTrials
AzTrials

Crohn's DiseaseNCT01736046

Comparison of Standard and Low Dose CT Enterography for Crohn's Disease

An observational study of Crohn's Disease, run by University of British Columbia at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The investigators will be assessing the efficacy of a Model Based Iterative Reconstruction algorithm (MBIR) as a noise reduction tool in computed tomographic (CT) examinations for Crohn's Disease. Read more about this study

Who is it for?
Ages 19 to 80 years
Conditions the study is for
Crohn's Disease
What is being tested?
CT Enterography
Type of treatment
Surgery or procedure
How many people
163 participants
Where
1 siteCanada
Study dates
Dec 2012to Mar 2015
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients suspected of having Crohn's Disease who are referred for CT Enterography examination by their gastroenterologist

Who may be able to join

  • Patients age 19 years or older with suspected or known inflammatory bowel disease referred to the St. Paul's Hospital Radiology department for CT Enterography examination will be eligible to participate.

Who cannot join

  • Patients unable to tolerate oral contrast media ( PegLyte (polyethylene glycol) for bowel distension or with kidney disease (gfr<60) where intravenous contrast would be contraindicated.
  • Patients with a known or suspected allergy/reaction to contrast material.
  • Pregnant patients Note: As per standard of care in the SPH radiology department, a screening pregnancy test will be done if the patient is of child bearing potential and is not sure that they are pregnant.
  • Patients who are unwilling to sign the consent form will not be eligible for participation.

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • St. Paul's Hospital

    Vancovuer, British Columbia, V6M 3J9

Other trials in Canada

About this study

Official title: Effects of CT Reconstruction Algorithm on the Quantitative Assessment of Crohn's Disease: A Comparison of Standard and Low Dose CT Enterography

The investigators will be assessing the efficacy of a Model Based Iterative Reconstruction algorithm (MBIR) as a noise reduction tool in computed tomographic (CT) examinations for Crohn's Disease. MBIR is computer adapted mathematical calculation technique that generates CT images with less picture degradation (noise) than traditional computer reconstruction techniques such as FBP (Filtered Back Projection) and ASIR (Adaptive Statistical Iterative Reconstruction), for enteric Crohn's Disease findings.

The research involves collection of data from subjects standard of care diagnostic CT scan and from a research low radiation dose scan performed immediately following their diagnostic scan. We will determine the impact on image quality, interpretability, and Crohn's Disease findings of the low dose scan compared to the standard of care scan.

FBP, MBIR, and ASIR are post processing tools that do not alter the scan acquisition itself.

Read the detailed description
  1. PURPOSE The purpose of this study is to assess the efficacy of a new model based iterative reconstruction algorithm as a noise reduction tool and to compare its sensitivity for the findings of enteric Crohn's Disease with the sensitivity of FBP or ASIR CT Enterography findings in enteric Crohn's Disease. Definitions: Iterative reconstruction: A computer adapted mathematical calculation technique that allows the ability to generate CT images with less image noise (picture degradation) than traditional image reconstruction techniques. Reconstruction algorithms are computer adapted mathematical calculations applied to raw data during image reconstruction.
  2. HYPOTHESIS The use of different CT reconstruction algorithms will allow the quantitative assessment of small bowel Crohn's Disease (CD) while exposing patients to lower radiation doses. MBIR and ASIR will provide images with lower noise and similarly accurate quantification of CD. Additionally, MBIR will allow acquisition of CT data at very low radiation doses, with comparable image quality and quantitative assessment of CD compared to higher radiation dose acquisitions performed utilizing FBP and ASIR. MBIR will not be inferior to FBP or ASIR in assessing findings related to Crohn's Disease on CT enterography (CTE). Definitions MBIR: Model Based Iterative Reconstruction algorithm FBP: Filtered Back Projection ASIR: Adaptive Statistical Iterative Reconstruction
  3. JUSTIFICATION Computed tomography imaging traditionally relied upon filtered back projection (FBP) for image reconstruction. This technique uses relatively little computing power, but requires a number of assumptions be made about the data acquisition itself that result in an increase in image noise. The use of iterative reconstruction techniques has recently started to take place in CT imaging. The major benefit of iterative reconstruction techniques is the ability to generate CT images with less image noise. This noise reduction allows for tube current reduction with IR images, limiting radiation dose in a linear manner. Model based iterative reconstruction (MBIR), is replacing the older iterative technique, adaptive statistical iterative reconstruction (ASIR). MBIR utilizes more accurate modeling and early research suggests MBIR images may be reconstructed from CT acquisitions that use significantly decreased radiation dose, with similar image quality compared to both ASIR and FBP. FBP, MBIR, and ASIR are post processing tools that do not alter the scan acquisition itself. Iterative reconstruction algorithms have garnered increased interest, especially with elevated public concern about radiation dose . MBIR techniques have not yet been validated in CT examinations acquired for evaluation of Crohn's Disease (CD). Clinical history, physical examination, laboratory investigations and endoscopy have been used to identify and evaluate the extent and severity of Crohn's Disease along with imaging studies to assist in the evaluation of the small bowel involvement of CD. CT Enterography has become the preferred imaging modality for assessing small bowel involvement in inflammatory bowel disease. The dose reduction properties of MBIR are particularly appealing in this area of CT imaging as multiple scans may be performed over time to assess progression or relapse of disease and response to treatment. Calprotectin is a protein found inside the cytoplasm of the immune cells within the intestine known as neutrophils, granulocytes and macrophages. Under conditions of mucosal inflammation as seen in inflammatory bowel disease, calprotectin is released into the lumen of the bowel and excreted in the stool. Fecal Calprotectin levels can be measured and serve as a biological marker of the degree of mucosal inflammation in the bowel. Fecal calprotectin levels have not been previously correlated with the degree of mucosal inflammation seen on CT Enterography.
  4. OBJECTIVE To determine the impact on image quality, interpretability, and Crohn's Disease findings of low dose computed tomography enterography (CTE) images acquired with a new model based iterative reconstruction algorithm as compared to standard image reconstruction.
  5. RESEARCH METHOD The research is a prospective non randomized study of 163 consecutive patients who are clinically referred for CT Enterography.
  6. STATISTICAL ANALYSIS

Using sensitivity of the CTE to calculate sample size, the planned sample size for this study is 163 subjects. The study will be powered at 80% to demonstrate that the lower radiation CTE (ASIR and MBIR) is non-inferior (type I error rate of 2.5%, one sided) to the standard CTE. The sensitivity of the standard CTE is assumed to be 0.77 based on a pooled estimate [7]. 0.1 is chosen as the non-inferiority margin. The correlation between the two procedures is considered in the sample size calculation. We assume that the prevalence of Crohn's Disease is 80% among the target population.

Using the nQuery statistical program, with the assumption that the proportion of discordant examinations is 0.15(or the conditional probability of positive finding in standard CTE is 0.90 if given a positive finding on the ASIR or MBIR CTE), the sample size needed to detect no more than 0.1 difference in sensitivity of the two procedures for patients with disease is 118, with a 80% power and a type I error of 0.025, one sided. Assuming that 80% of target population will have disease, approximately 148 subjects will need to be recruited. We have factored in a 10% drop out rate ( patients who leave the study for any reason) bringing the total number of patients to be recruited to 163.

Image quality scores and quantitative analysis will be compared using both standard and the novel reconstruction algorithms. These results will also be compared to the acquired FC levels. Because each patient examination will receive multiple reconstructions, a mixed-model analysis will be conducted to account for repeated observations within patients. Repeated measures analysis of variance will be conducted separately for each outcome (signal, noise, SNR, proportion of interpretable segments, and image quality) against the type of reconstruction used. A 0.05 significance level will be used for all repeated measures and analysis.

Primary Endpoint:

FBP, ASIR and MBIR will each be compared to the reference standard described below. The endpoint will be the ability of each method to accurately identify the presence or absence of Crohn's Disease (CD) as compared to the reference standard.

Reference Standard:

Dr. B. Bressler, the principal investigator, is a gastroenterologist with an expertise in inflammatory bowel disease (IBD). Dr. Bressler will review all of the available clinical parameters including history and physical exam findings, ileocolonoscopy findings if available and laboratory parameters including bloodwork and Fecal Calprotectin levels. The gastroenterologist will not be blinded to the subject's identity. Based on his review of the above parameters, he will rate the presence of small bowel CD as definitely active, probably active, inactive (remission) or absent.

Conditions
Crohn's Disease
Being tested
CT Enterography
Keywords
CT Enterography, Crohn's Disease, Inflammatory Bowel Disease
Medical subject headings
Crohn Disease, Inflammatory Bowel Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CT EnterographyRadiation

    Also called CT Scan to include imaging of the small bowel and colon

    Diagnostic CT Enterography Scan (CTE)

    Subjects will have their scheduled diagnostic CTE scan done according to St. Paul's Hospital radiology department standard procedures. Subjects will be randomly assigned to undergo a low dose CT Enterography scan either before or after the diagnostic scan. The radiologists who are blinded to the technique used will then interpret the scans to look for signs of Crohn's disease. The low dose scan will be compared to the standard scan in terms of it's ability to detect signs of Crohn's disease.

Study groups in NCT01736046
Study groupRoleWhat they receive
Crohn's Disease patientsAll patients referred for CT Enterography will be undergo both standard and low dose CT Enterography
Receives: Radiation: CT Enterography

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sensitivity of Low Dose and Standard dose CTE for detecting active Crohn's Disease

    FBP, ASIR and MBIR will each be compared to the reference standard. The endpoint will be the ability of each method to accurately identify the presence or absence of Crohn's Disease (CD) as compared to the reference standard.

    Measured: 1 year

Secondary outcomes (1)
  1. Correlation of Fecal Calprotectin with Radiology findings of Crohn's Disease

    Fecal Calprotectin levels will be measured and the results will be correlated with findings suggestive of Crohn's Disease on CT Enterography

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Nov 2012 (estimated)
  2. Study startDec 2012
  3. Primary completionJan 2015
  4. Study completionMar 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
163 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01736046
Sponsor's protocol ID
H12-02211
Status last verified
Jul 2015
First submitted
6 Nov 2012
Last updated
31 Jul 2015
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Crohn's Disease, run by University of British Columbia at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Jul 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sensitivity of Low Dose and Standard dose CTE for detecting active Crohn's Disease (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in